Towards a commercial process for the manufacture of genetically modified T cells for therapy.
about
Current clinical immunotherapeutic approaches for head and neck cancerClinical manufacturing of CAR T cells: foundation of a promising therapyCAR T Cell Therapy: A Game Changer in Cancer TreatmentRecent Developments in Cellular Immunotherapy for HSCT-Associated ComplicationsInnovative regenerative medicines in the EU: a better future in evidence?Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapyGlobal Manufacturing of CAR T Cell Therapy.Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials.Bioengineering solutions for manufacturing challenges in CAR T cells.Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Therapeutic T cell engineering.More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.Prospects for combined use of oncolytic viruses and CAR T-cells.Immunotherapy for Chronic Hepatitis B Virus Infection.Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective.Perspectives on Manufacturing of High-Quality Cell Therapies.Recent advances in bioreactors for cell-based therapies.
P2860
Q26745411-7A6BBBEB-29F9-40BD-9847-D43CDDEA429EQ26747037-F723A483-524C-441A-BFE7-C1B252DE79F2Q26822769-A55CF7FA-052A-4558-9EA1-5348D89B9C5FQ28079823-98B2F17B-A334-46B4-9BA0-E5982160E955Q36300179-4545659A-ACF5-4061-9E03-7A3727F71290Q37366489-52D8E4A1-5FBE-4B92-8E2C-22C6B380007EQ37717884-FC91E04A-96ED-4FC1-80B1-1CA3DE721380Q38604100-83FD140B-0E11-4B19-A01D-FA1CDB9A7CAAQ38637370-F8CC2C45-5C4B-4097-9957-715EAE0D6B1CQ38827775-CCD4D43D-E770-4453-B62D-27AB4ADD6748Q39189908-E2756E74-A394-4605-92BA-8F0717CF9AA9Q40199809-27F47238-977F-4CCB-B982-DC797774D5E3Q41449200-7F045618-5534-4F31-9B09-179DA986000CQ41450925-E2B38A02-2DD4-4448-A588-6454920DDC73Q47103891-30056C75-DBCF-4513-B4ED-CAA237007651Q47556416-8C69011E-F2BD-481C-8307-481D7DA96E8CQ50032278-34CFA91E-2C81-4D9B-B847-B57855CF4D76Q50893433-D85139EC-5450-4968-A60E-55DFA128D7BDQ54966771-52153010-A657-44DC-A642-54ABDD0C7A6A
P2860
Towards a commercial process for the manufacture of genetically modified T cells for therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Towards a commercial process f ...... modified T cells for therapy.
@en
type
label
Towards a commercial process f ...... modified T cells for therapy.
@en
prefLabel
Towards a commercial process f ...... modified T cells for therapy.
@en
P2093
P2860
P921
P356
P1433
P1476
Towards a commercial process f ...... modified T cells for therapy.
@en
P2093
A D Kaiser
B Dropulic
B Schröder
M Assenmacher
P2860
P2888
P356
10.1038/CGT.2014.78
P5008
P577
2015-01-23T00:00:00Z
2015-03-01T00:00:00Z